pegylated interferon alfa
ApprovedBiologic
Merck & Co.pegylated interferon alfa is one of 241 biologic programs targeting Glioma. It is currently in Approved.
7
Indications
11
Total Trials
1
Active Trials
240
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1pegylated interferon alfa
Merck & Co.Approved
Velban
EEastern Cooperative Oncology Group
Preclinical
Oncaspar
SServier
Preclinical
Wellcovorin
GGlaxo Dba Glaxosmithkline
Preclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
PEG-Intron
Merck & Co.Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Chronic Hepatitis4 trials
The Clinical Cure Project of Chronic Hepatitis B in China
Active, not recruiting·TThird Affiliated Hospital, Sun Yat-Sen University·Phase 4·NCT04035837·30,000 enrolled
Show 1 more trial
Pegylated Interferon Alone or in Combination With Ezetimibe for Patients With Chronic Hepatitis D
Unknown status·—·Phase 2·NCT03105310·20 enrolled
Melanoma2 trials
Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma
Unknown status·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00006249·1,258 enrolled
Lymphoma1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for pegylated interferon alfa. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Approved[1]
- Company